Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: September 13, 2005
Last updated: February 23, 2017
Last verified: February 2017

This trial is conducted in Europe. Objective(s): To evaluate the effect of human growth hormone on infants aged 1 to 2 years with chronic renal insufficiency (CRI) and growth retardation despite an adequate dietary intake.

Trial Design: This is an open, parallel group clinical trial with a duration of one year, in which period 50% of patients will receive GH treatment and the other 50% will act as a control group, without treatment.

Trial Population: The trial will involve a total of 16 infants aged from 12±3 to 24 months suffering chronic renal insufficiency (Glomerular Filtration Rate less than 60 ml/min/1.73 m2), and growth failure and undergoing conservative treatment or peritoneal dialysis. Include the key inclusion and exclusion criteria.

Condition Intervention Phase
Chronic Kidney Disease
Chronic Renal Insufficiency
Drug: somatropin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Open Randomized Trial Examining the Growth and Safety Effects of Treatment With Recombinant Growth Hormone on Infants Aged 1 to 2 Years With Growth Retardation Secondary to Chronic Renal Insufficiency

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • To evaluate the effect of growth hormone on infants aged 1 to 2 years with CRI and growth retardation growth retardation despite an adequate dietary intake [ Time Frame: after 1 year of treatment ]

Secondary Outcome Measures:
  • Secondary objectives are to assess the safety of rhGH treatment in these infants. Safety assessment will include evaluation of renal function, Bone, IGF-I, IGFBP3 and psychological development

Enrollment: 16
Actual Study Start Date: January 29, 1998
Study Completion Date: December 21, 2005
Primary Completion Date: December 21, 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   9 Months to 15 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients will be infants of both sexes aged 12 ± 3 months with chronic renal insufficiency and growth retardation.
  • To be included in the trial, patients must meet all of the following inclusion criteria a.)-c.):
  • a.) Male or female infants with a chronological age of 12 ± 3 months
  • b.) Chronic renal insufficiency with Glomerular Filtration Rate less than 60 ml/min./1.73m2, according to the method used routinely in each participating center
  • c.) Growth retardation documented at the start of the trial, according to the following criteria: Length less than -2 SDS by chronological age and sex and linear growth velocity <P50 according to the Hernández standards and to Lubchenko in the case of infants born prematurely (<37 weeks)
  • Conservative treatment or chronic peritoneal dialysis
  • Euthyroid
  • The parent or guardian must give informed consent to the child's participation in the study before any trial related activities. Trial related activities are any procedures that would not have been performed during the normal management of the subject
  • Optimal nutritional management criteria met
  • Appropriate metabolic control for severe hyperparathyroidism, hydroelectrolyte balance, acid-base balance and calcium-phosphorus balance

Exclusion Criteria:

  • Any primary endocrinological disorder and severe renal osteodystrophy.Other causes, apart from CRI, giving rise to growth retardation.Hydrocephalus.
  • Known or suspected allergy to the trial product or related products.
  • Treatment with corticosteroids within the last six months.
  • Renal disease due to the Fanconi syndrome or to oxalosis (except if not under dialysis).
  • Known or suspected malignancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00184769

Novo Nordisk Investigational Site
Coimbra, Portugal, 3000-075
Novo Nordisk Investigational Site
Lisboa, Portugal, 1160-045
Novo Nordisk Investigational Site
Lisboa, Portugal, 1649-035
Novo Nordisk Investigational Site
Porto, Portugal, 4200-319
Novo Nordisk Investigational Site
Badajoz, Spain, 06080
Novo Nordisk Investigational Site
Baracaldo, Spain, 48903
Novo Nordisk Investigational Site
Esplugues Llobregat, Spain, 08950
Novo Nordisk Investigational Site
Lugo, Spain, 27004
Novo Nordisk Investigational Site
Madrid, Spain, 28009
Novo Nordisk Investigational Site
Madrid, Spain, 28041
Novo Nordisk Investigational Site
Madrid, Spain, 28046
Novo Nordisk Investigational Site
Málaga, Spain, 29011
Novo Nordisk Investigational Site
Oviedo, Spain, 33006
Novo Nordisk Investigational Site
Pamplona, Spain, 31008
Novo Nordisk Investigational Site
San Sebastián, Spain
Novo Nordisk Investigational Site
Santa Cruz de Tenerife, Spain, 38010
Novo Nordisk Investigational Site
Santander, Spain, 39008
Novo Nordisk Investigational Site
Santiago de Compostela, Spain, 15705
Novo Nordisk Investigational Site
Sevilla, Spain, 41013
Novo Nordisk Investigational Site
Zaragoza, Spain, 50009
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novo Nordisk A/S Identifier: NCT00184769     History of Changes
Other Study ID Numbers: GHCRF/E/2
Study First Received: September 13, 2005
Last Updated: February 23, 2017

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Kidney Diseases
Renal Insufficiency
Urologic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2017